Company Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States.
The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis.
Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology.
The company was incorporated in 2015 and is based in South San Francisco, California.
| Country | United States |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Dr. Christopher J. Kirk Ph.D. |
Contact Details
Address: 4000 Shoreline Court South San Francisco, California United States | |
| Website | https://www.kezarlifesciences.com |
Stock Details
| Ticker Symbol | KZR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645666 |
| CUSIP Number | 49372L100 |
| ISIN Number | US49372L1008 |
| Employer ID | 47-3366145 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher J. Kirk Ph.D. | Co-Founder, Chief Executive Officer & Director |
| Mark Schiller | Chief Legal Officer |
| Dr. Jack Taunton Ph.D. | Co-Founder |
| Dr. Neel K. Anand Ph.D. | Senior Vice President of Research & Drug Discovery |
| Gitanjali Jain | Senior Vice President of Investor Relations & External Affairs |
| Joe Tedrick | Vice President of Human Resources |
| John Franklin Fowler | Co-Founder & Director |
| Pattie Chiang | Senior Vice President & Corporate Controller |
| Zung To | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 03, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 8-A12B/A | [Amend] Filing |
| Oct 28, 2024 | 8-K | Current Report |
| Oct 17, 2024 | 8-A12B | Filing |
| Oct 17, 2024 | 8-K | Current Report |
| Oct 10, 2024 | 8-K | Current Report |